Novavax controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2022
COVID-19 manufacturing delays and regulatory scrutiny
Novavax faced public and investor criticism over delays in demonstrating consistent commercial-scale manufacturing and completing regulatory submissions for its COVID-19 vaccine. These issues contributed to delayed access in the United States and legal claims concerning earlier company statements.
2021
Securities litigation over COVID-19 manufacturing and regulatory disclosures
Investors filed a purported securities class action alleging that Novavax and certain senior executives made misleading statements about the company's ability to manufacture its COVID-19 vaccine at commercial scale and obtain regulatory approval on anticipated timelines. The company contested the allegations, and the court dismissed some claims while allowing other claims to proceed at an earlier stage of the litigation.